ProBNP Detection Device Using Segmented Capture Regions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current assays for detecting proBNP, BNP, and NT-proBNP in patients with congestive heart failure (CHF) suffer from inaccuracies due to assay pollution and lack of discriminative accuracy, which can lead to difficulties in monitoring the effectiveness of therapies like ARNI.
Innovation Solution
The development of devices with multiple capture regions specifically designed to capture and distinguish between proBNP, BNP, and NT-proBNP, minimizing assay pollution and improving detection accuracy by using distinct epitopes for labeling and capturing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing immunoassays target common epitopes for BNP and NT-proBNP detection, then the assay can detect these peptides, but assay pollution occurs due to cross-reactivity with proBNP
Solution Approach 1:
The assay is divided into three separate capture regions, each targeting a specific peptide (proBNP, BNP, or NT-proBNP) with its own specific antibodies. This segmentation prevents cross-reactivity and assay pollution by ensuring that each region detects only its intended target without interference from the other peptides.
Solution Approach 2:
Each capture region is designed with specific local characteristics - different antibody specificities tailored to each peptide's unique epitopes. The proBNP capture region uses antibodies specific to proBNP epitopes, while BNP and NT-proBNP regions use antibodies specific to their respective epitopes, creating locally optimized detection zones that prevent cross-reactivity.
2Device complexity
If a single assay detects BNP and NT-proBNP, then the assay is simpler, but it cannot discriminate between proBNP and processed peptides
Solution Approach 1:
The assay uses three separate capture regions with specific antibodies for proBNP, BNP, and NT-proBNP. This segmentation allows simultaneous detection of all three peptides with high discrimination accuracy, as each region is optimized for its specific target peptide's unique epitopes.
Solution Approach 2:
The assay device performs multiple functions within a single integrated system - it simultaneously detects proBNP, BNP, and NT-proBNP using parallel capture regions. This multi-functional design provides comprehensive biomarker differentiation while maintaining a unified assay structure that can be applied to various clinical scenarios.
3Measurement precision
If venous puncture-based laboratory tests are used for BNP/NT-proBNP measurement, then accurate measurement is achieved, but the process is time-consuming and requires clinical care setting
Solution Approach 1:
The patent replaces complex mechanical venous puncture procedures with a simplified lateral flow assay system that can be performed using capillary or salivary samples. The assay uses fluid flow through a membrane structure to deliver samples to capture regions, eliminating the need for venous puncture and clinical laboratory infrastructure while maintaining measurement accuracy.
Solution Approach 2:
The assay is designed to be self-contained with all necessary reagents, capture regions, and detection mechanisms integrated into a single device. The lateral flow mechanism automatically separates and detects peptides without requiring external laboratory equipment or clinical care setting, enabling point-of-care testing that reduces time loss while maintaining precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These devices enable more accurate diagnosis and monitoring of CHF by providing a reliable and continuous measurement of natriuretic peptides, improving the differentiation between the three peptides and enhancing the assessment of heart failure management.
Implementation Method 1
a first capture region comprising a first capture species, wherein the first capture species binds to an epitope that is located within a region defined by amino acids 72-105 of SEQ ID NO: 2
Data Source
AI summary
The present disclosure provides a device for determining the presence of BNP, proBNP and NT-proBNP. The devices comprise multiple capture regions configured to selectively capture BNP, proBNP and NT-proBNP by specific binding of proBNP. Alternatively or additionally, the devices may capture and label epitopes to distinguish proBNP from NT-proBNP or BNP.